Renowned University of Pennsylvania professor takes on expanded leadership role to advance the company's science and scale its closed-loop cell signaling platform.
New chief strategy officer and chief marketing officer join to help lead the company’s next phase of growth at the frontier of AI and biology.
We have entered into an agreement with Novo Nordisk to acquire STEM-PD, a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease.
Cellular Intelligence has secured global rights to Novo Nordisk’s Parkinson’s program, a clinical-stage allogeneic cell therapy for Parkinson's disease with FDA Fast Track Designation.
New white paper details key technical milestones and validation of the company’s proprietary, capsule-based platform to accelerate breakthroughs across human health.
Somite.ai, a company pioneering foundation models for human stem cells, today announced a strategic investment from AMD Ventures.
Somite builds foundation models for human stem cells. We’ve just raised over $47M in Series A funding led by Khosla Ventures to accelerate development of DeltaStem, our foundation model to produce any cell type for any person.